Abstract: Since cyclooxygenase (COX) isozymes discovery, many papers and reviews have been published to describe the structural bases of COX inhibition, and to debate on the therapeutic and adverse effects of worldwide clinically used nonsteroidal anti-inflammatory drugs (NSAIDs), included COX-2 selective inhibitors (well known as Coxibs). COX-2 inhibition has been widely investigated, whereas the role of COX-1 in human pathophysiology is mostly not yet well ascertained. As time goes on, the cliché that the constitutively expressed isoform COX-1 is only involved in normal physiological functions, such as platelet aggregation, gastric mucosa protection and renal electrolyte homeostasis is going to be shattered. Low-dose aspirin, behaving as a preferential inhibitor of platelet COX-1, allowed to enlighten the role exerted by this isoenzyme in many mammalian cell types. This review would elucidate the most recent findings on selective COX-1 inhibition and their relevance to human pathology such as cancer, neuro-inflammation, cardioprotection, fever and pain. It would also focus on the design and development of new highly selective COX-1 inhibitors, useful tools in pharmacological studies aimed at gaining a deeper insight of the role of COX-1 in human health and disease. Among the traditional NSAIDs, other then aspirin and indomethacin, only few examples of selective COX-1 inhibitors (SC-560, FR122047, mofezolac, P6 and TFAP) have been so far identified. This review has also the scope to stimulate the development of novel drugs, which activity is COX-1 mediated.
INTRODUCTION
Cyclooxygenase (COX) is the enzyme responsible for the conversion of arachidonic acid (AA) into prostanoids ( Fig.  (1) ). It was identified over two decades ago, although aspirin, a cyclooxygenase inhibitor, has been commercially available (Bayer) since 1899 to treat inflammatory syndromes [1] . In the last years, two isoforms of COX produced from different genes have been identified, COX-1 and COX-2 [2] . In 2002, Simmons' group reported the discovery of a third cyclooxygenase isoform (COX-3) in dogs as an alternative splice variant of COX-1. They also showed that COX-3 was putatively the specific target of acetaminophen [3] . Canine COX-3 mRNA is identical to the COX-1 mRNA except that intron 1 is retained, and canine COX-3 peptide was expected to have COX activity because most of the amino acids sequence is identical to COX-1. Such results from dogs were then transferred to humans and rodents without critical evaluation of the experimental data.
In fact, it has been proved that COX-3 encodes proteins with completely different amino acids sequences with respect to COX-1 and COX-2 in rodents and humans, and lacks COX activity. For this reason, it is improbable that COX-3 plays a role in prostaglandin action-mediated fever and pain. Therefore, the possible clinical relevance of COX-3 as a drug-target is still to be understood [4] .
Besides, although several years have passed since the original publication [3] , there is no follow-up study that would confirm the COX activity of the canine COX-3 and its sensitivity to acetaminophen [4] . the two isoforms in mammalian biology have been accomplished. COX-1 is considered a "housekeeping gene" due to the constitutive low-levels of expression in most cell types and tissues. High levels of constitutive expression of COX-1 have, instead, been detected in the stomach and platelets. In contrast, the gene for COX-2 is a primary response gene with many regulatory sites; thus, COX-2 expression can be rapidly induced by bacterial endotoxin such as lipopolysaccharide (LPS), cytokines, such as interleukin (IL)-1 and tumor necrosis factor-(TNF-), growth factors (GF), and the tumor promoter phorbol myristate acetate (PMA) [5] . These differences in the regulation of COX-isozymes suggested that the major action of COX-1 is to mediate the gastrointestinal tract protection and modulate platelet function, whereas COX-2 is mainly involved in inflammation and pain. Traditional non selective non-steroidal anti-inflammatory drugs [(t)NSAIDs] which inhibit both COX-1 and COX-2, exert their therapeutic effects through inhibition of COX-2-dependent prostanoid biosynthesis and cause a gastrointestinal damage through the inhibition of COX-1. Therefore, to attenuate the gastrointestinal toxicity, NSAIDs selective for COX-2 (coxibs) were developed [6] [7] [8] . The use of coxibs in the humans allowed to unravel the protective role of COX-2 for the cardiovascular system, mostly through the generation of the prostacyclin [9] . The role of COX-1 in the humans for platelet activation was enlightened by the use of low-doses of aspirin [10] , a preferential inhibitor of platelet COX-1, whereas the action of COX-1 in protecting the gastrointestinal tract was demonstrated indirectly using coxibs which spare COX-1 [6] . Reduced availability of highly selective COX-1 inhibitors [11] led to the use of genetic mouse models of selective deletion of COX-1, as a strategy to enlighten the potential pathogenic contribution of prostanoids synthesized via COX-1, e.g. to inflammatory arthritis [12] , atherogenesis [13] , intestinal polyposis [14] and skin carcinogenesis [15] . The concept that COX-2 is the only COX isoform involved in inflammation has also been challenged by a number of studies [16] [17] [18] [19] . It is now believed that COX-1 is responsible for the primary prostanoid response to inflammatory stimuli (particularly, in cells and tissues where it is Perrone et al. costitutively and predominantly expressed), whereas COX-2 becomes the major contributor to prostanoid synthesis specially in inflammation progress [20] [21] [22] [23] . So, this review aim at summarizing the current knowledge of the role of cyclooxygenase-1 isozyme in different physiological conditions and diseases onset and progress ranging from inflammation to cancer, also focusing the clinical and preclinical evidences on the sole involvement of COX-1 in pathophysiology of acute and chronic disorders (i.e., COX-1 enzyme is involved in pain processing and sensitization in spinal cord and gracile nucleus after surgery [24] and is overexpressed in human ovarian cancer, where it promotes angiogenic growth factor production [25] ).
In addition, a special attention will be given (a) to the assays used to determine the activity and selectivity (often discordant and assay dependent) of the COX inhibitors (selectivity values are used to classify the large number of clinically used NSAIDs), and (b) the main structure-activity relationship investigations, so far reported, performed to identify the few known COX-1 selective inhibitors (Fig. (2) ).
COX-1 EXPRESSION IN THE PATHOPHYSIOLOGY OF DIFFERENT BODY DISTRICTS
COX-1 distribution in many tissues and its role is not completely assessed. However, its expression is constitutive in many cell/tissue types, where it cooperates in maintaining normal homeostatic functions.
In this section, we briefly describe the COX-1 distribution in the most important body districts in health and disease.
COX-1 and COX-2 coexist in the vasculature and macrophages, and expression is induced in atherosclerotic plaque. Both isoforms are present in mature megakaryocytes, but mature platelets predominantly express COX-1. Enhanced platelet activation and de novo thromboxane (TX) biosynthesis by vascular cells and monocytes are COX-1-mediated processes [26] .
In the normal heart, COX-1 is considered a constitutive isoform and it is supposed to be involved in maintaining normal homeostatic functions [27] . It is expressed in blood vessels and endocardium, but not in cardiomyocytes [28] . A strong expression of COX-1 was found in the endothelial and smooth muscle cells in blood vessels of the heart, in accordance with the suggested role of COX-1 prostanoids in blood vessels: control of the blood vessel tone and inhibition of thrombosis [29] . It is well known that prostaglandins synthesized via the COX pathway are important mediators in inflammation after myocardial infarction (MI) [30] [31] [32] [33] , and enhanced expression of COX-1 was found in MI: it was strongly expressed in neutrophil granulocytes which infiltrate the interstitium, as well as in capillaries, myofibroblasts, and mononuclear inflammatory cells of the granulation and fibrous tissue, suggesting that COX-1 is involved in the healing process after MI. Moreover, as recently reported by Radi et al. [34] , in other districts of cardiovascular system a direct involvement of COX-1-derived prostanoids could contribute to the pathology evolution. In fact, although in normal conditions COX-1 activity promotes the release of vasodilatory prostacyclin (PGI 2 ), in pathological conditions such as hypertension the COX-1 isoform contributes to contracting prostanoid biosynthesis, as demonstrated in the pathogenesis of Angiotensin II-induced endothelial dysfunction [35] , where a downregulation of COX-2 and a simultaneous induction of COX-1 expression in vessels from Ang II-infused animals was revealed by immunohistochemical analysis.
In human endothelial cells, both COX isoforms appear to be important for the production of PGI 2 , with COX-2 provid- ing the hydroperoxide tone necessary for COX-1 activity. On the contrary, in conditions such as those defined by intracellular glutathione depletion, or whenever significant amounts of arachidonic acid and hydroperoxides may be made available, such as during platelet adhesion and activation, COX-1 may be freed from its partial dependence on COX-2, becoming the main activity leading to the production of endothelial prostacyclin. These data clearly define the effects of cyclooxygenase inhibitors on endothelial cells and their potential clinical use, by pointing to a critical role of COX-1 in prostacyclin generation, at least under conditions where increased substrate and lipid hydroperoxide availability are observed [36] .
More generally, COX-1 activity towards AA is likely regulated by hydroperoxide tone such that in the early stage of cell activation by cytokines and tumor promoters, COX-1 is functional (and COX-2 is absent), whereas in the later stage COX-1 and COX-2 are both present but only COX-2 is functional.
In kidneys, prostanoids play an important role in blood pressure regulation and hemodynamics. COX-1 is the most abundant isoform in the kidney districts such as distal convoluted tubules, collecting ducts, vascular endothelial cells and medullary collecting ducts, whereas less cytoplasmic levels are present in cortical interstitial cells, proximal convoluted tubules and in the macula densa. Nephrotoxic syndromes and interstitial hydrostatic pressure modification may result from renal prostaglandins (PGs) level reduction after (t)NSAIDs administration in anti-inflammatory therapies, because changes in the sodium excretion regulation occur in the collecting ducts of the nephron, where COX-1 is widely expressed. While the selective COX-2 inhibitors spare homeostatic COX-1 activity in the kidney, non selective NSAIDs may adversely influence blood pressure control, as demonstrated in COX-1 deficient mice versus wild-type controls [37] . Hence, studies performed by using selective COX-1 inhibitors could unequivocally reveal if NSAIDs aggravate renin-independent hypertension, through renal COX-1 inhibition responsible for sodium excretion [37] .
COX-1 is the predominant isoform in gastrointestinal (GI) [38] apparatus of various species. It is found in the mucosal epithelium, vascular endothelium, smooth muscle cells of the tunica muscularis, gastric fundus, corpus, antrum and/or pylorus, duodenum, jejunum, ileum, cecum, and colon. However, in humans, the highest and lowest areas of COX-1 expression are in the small intestine and gastric fundus/antrum, respectively [39] . Various experiments suggest that COX-1 deficiency or inhibition is compatible with normal small intestinal integrity [40] . Langenbach et al. reported that COX-1 knockout mice do not spontaneously develop gastric damage. COX-1 -/-mice are normal except for a decrease in intestinal PGE 2 levels [40] . COX-1 inhibition alone does not cause GI injury.
COX-1 is constitutively expressed in various areas of the brain, where it is involved in a previously unrecognized proinflammatory role such as the pathophysiology of acute and chronic neurological disorders [41] , pain processing and sensitization in spinal cord and gracile nucleus after surgery [24] . COX-1 predominant localization in microglia revealed a possible involvement in neuroinflammatory response and neuronal pathologies, whereas in COX-1-deficient mice studies, a decreased neuroinflammatory response and neuronal damage in response to lipopolysaccharide (LPS) was found.
COX-1 is mainly expressed in normal bone, where PGE 2 is the most abundant PG produced by osteoblastic cells and plays many roles in bone metabolism. Adverse and normal effects of (t)NSAIDs and COX-2 selective inhibitors are studied in different preclinical models of orthopaedic diseases, but variable and conflicting results were reported, thus selective COX-1 inhibition could be useful to better understand the role of COX-1 activity derived PGs in the process of bone healing [37, 42] .
Specifically, COX-1 expression is up-regulated in cancer such as human breast cancer [43] , human prostate cancer [44] , and murine models of lung tumorigenesis [45] . COX-1, but not COX-2, is highly expressed in humans and mice epithelial ovarian cancers [46] , and enhanced tumorigenicity [47] in endothelial cells implanted in mice is associated also with COX-1 overexpression. Up-regulation of COX-1 was also found in squamous cell carcinoma and adenocarcinoma of the human cervix, suggesting that both COX-enzymes and/or their products may contribute to modulate the tumours genesis and the expression of factors responsible of the development of cervical cell neoplasias [48] .
COX-1 AND ATHEROSCLEROSIS
The role of prostacyclin (PGI 2 ) and thromboxanes (TXA 2 /TXB 2 , Fig. (3) ) in the haemostasis is well known. PGI 2 acts as a vasodilator autacoid by reducing blood pressure in primary cardiovascular haemostasis, prevents plaque formation and progression through inhibition of platelet activation and vascular smooth-muscle cell migration and proliferation.
TXA 2 is responsible of activation, aggregation and platelet enrolment in haemostasis and is responsible of plateletvessel wall interactions.
While haemostasis is necessary for survival, atherosclerosis and thrombosis result from uncorrected activation of the normal haemostatic process in the site of vessel wall damage, pathological conditions that pose significant health risks.
Alteration of platelet activity influences the development of atherosclerosis and contributes to the evolution of lesions.
COX-1 plays an important role in the pathogenesis of atherothrombosis, because COX-1 prostanoids have a part in the ongoing hardening of the arteries. Studies with selective COX inhibitors revealed that enhanced PGI 2 levels derive both from COX-1 and COX-2, whereas high TXA 2 levels depend mainly on platelet COX-1 expression. COX-1 is expressed in increased amounts in atherosclerotic plaques and predominantly in vascular smooth muscle cells; moreover, the enhanced platelet activation glycoprotein (GP) IIb/IIIamediated and de novo TX biosynthesis by vascular cells and monocytes are COX-1-mediated processes in thrombosis [26] .
Aspirin shows antithrombotic effects by the irreversible inhibition of platelet COX-1 catalytic activity: site-directed mutagenesis studies [49] well established that aspirin acetylates Ser-530 of COX-1 and permanently blocks the binding and AA processing through the inhibition of COXcyclooxygenase activity.
Platelets are unable to replace inactivated COX-1 because are anucleated, thus, aspirin is a therapeutic advantage against thrombosis acting as COX-1 inhibitor. Unfortunately, variability in the sensitivity of patients to aspirin interferes with the necessary complete and persistent suppression of TXA 2 biosynthesis in cardio-protection, by causing COX-1 dependent "aspirin resistance". TXA 2 formation might remains elevated in patients with cardiovascular disease on doses of aspirin that fully suppress platelet COX-1, suggesting that could be involved the "de novo" synthesis of COX-1 in acetylated platelets [50] and other tissue sources for COX-1/TXA 2 unreachable by standard doses of aspirin [51] . On atherogenesis, TX is produced not only by platelet TX synthase, but also by macrophages, endothelial cells and smooth muscle cells depending on the stage of atherosclerotic lesion formation and the development of the diseases [52] .
Selective COX-1 inhibitors could be new therapeutic agents as antiplatelet drugs in cardioprotection therapies, mainly when aspirin fails, and in the acute treatment of arterial thrombosis, and also useful as tools to investigate the role of COX-1 in atherosclerosis being not fully understood.
Few studies are available on this point: the administration of SC-560, a selective COX-1 inhibitor, dramatically reduced atherosclerotic lesion formation in cholesterol diet rich apoE -/ -mouse model [53] , but did not induce regression or prevent the progression of lesions already developed, implicating COX-1 in the earlier stages of lesions formation [53] .
COX-1 AND ENDOTHELIAL DYSFUNCTION
COX activity is one of the key elements in endothelial dysfunction and PGs play a major role in modulating vascular tone (Fig. (4) ). Under physiological conditions, PGI 2 is the major prostanoid identified and released by endothelial cells mediating some protective effects on the vascular wall, including relaxation and inhibition of platelet aggregation and adhesion [54] . TXA 2 counteracts PGI 2 action, specifically acting on thromboxane-prostanoid (TP) receptors mainly located on smooth muscle cells where it causes vasoconstriction [55] . On the contrary, under pathological conditions, such as inflammation or atherosclerosis, the PGI 2 production decreases, and COX-derived vasoconstrictor substance release, including TXA 2 , becomes predominant [56] .
Specifically, in a murine model of Ang II-induced hypertension, COX-1-derived prostanoids acting on TP receptors are involved [35, 57] , whereas in rat renal cortex by Ang II, an attenuation of COX-2 expression was observed [58, 59] . Further, in aorta from spontaneously hypertensive rats, an animal model of oxidative stress, increased reactive oxygen species (ROS) production induces the production of COX-1-derived contracting prostanoids, which, in turn, stimulate TP receptors [55] .
Thus, ROS might be the key intermediates whereby Ang II interacts with the COX pathway to induce endothelial dysfunction.
In vessels from Ang II-infused mice, SC-560 (COX-1 inhibitor), but not DFU (COX-2 inhibitor), improved the relaxant response to acetylcholine without any effect on sodium nitroprusside, indicating that COX-1, but not COX-2, contributes to the pathogenesis of Ang II-mediated endothelial dysfunction as a consequence of the existence of a downregulation of COX-2 and a simultaneous induction of COX-1 strong expression.
Besides, the acute pressor effect of Ang II was abolished in COX-1-deficient mice [60] . More recently, COX-1 knockout mice chronically treated with Ang II showed a significant abrogation of hypertension [57] . However, COX-1 blockade improved only in part the Ang II-induced endothelial dysfunction, indicating a residual direct and specific COX-1-independent effect of Ang II on the vascular wall [61] .
These findings allow to propose that the oxidant excess, produced by NAD(P)H oxidase activation secondary to Ang II infusion, accounts for COX-1 stimulation, but not overexpression, to transform AA into contracting prostanoids, which then diffuse to activate responsive TP receptors. COX-1 could be itself a source of oxidative stress or produce any substance able to directly interact with NO, because COX-1 blockade did not increase the blunted inhibitory effect of L-NMMA on endothelial relaxation in Ang II-infused animals.
Oxidative stress, independently from its source, is able to stimulate COX-1 to produce contracting prostanoids different from TXA 2 but acting on TP receptors. This mechanism might significantly contribute to the atherosclerotic damage mediated by Ang II [35] .
COX-1 AND NEUROINFLAMMATION
Recently, some trials have been performed to find out clinical and pre-clinical evidence of COX-1-mediated proinflammatory effects in neurodegenerative disorders and in models of neuroinflammation [41] .
Neuroinflammation is an important mechanism in the defense response to pathogenic events, traumatic injury and environmental toxins, but it is also recognized as a major contributor to various neurological and neurodegenerative diseases [62] .
An innate immune response is mediated by microglia that contributes to the progression of the diseases [63] [64] [65] . Activated microglia produce several proinflammatory and neurotoxic mediators including complement, cytokines, chemokines, AA and its metabolites (Fig. (1) ), and reactive oxygen and nitrogen species, several of which contribute directly to neuronal injury [65] [66] [67] .
COX-1 and COX-2 play a complex role in the mechanism of central nervous system (CNS) inflammation. Besides, COX-1 (predominantly localized in microglia) plays a previously unrecognized part in the neuroinflammation, a key stage in the development of several neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, traumatic brain injury, HIV-associated dementia, ischemic stroke and epilepsy, whereas COX-2, mainly localized in pyramidal neurons, is expected to predominantly contribute to increase PG synthesis in response to insults that directly challenge neurons, such as ischemia and exitotoxicity. Under these circumstances, COX-2 inhibition seems to afford protection without altering the inflammatory responce. Thus, the type of insult, the cellular target of the stimulus and whether neuroinflammation is a primary or a secondary response could determine whether COX-2 activity mediates neurotoxicity or neuroprotection [41] . In particular, genetic ablation or pharmacological inhibition of COX-1 activity attenuates the inflammatory response and neuronal loss. This indicates that NSAIDs with higher selectivity for COX-1 rather than COX-2 are more likely to reduce neuroinflammation [41] , and should be further investigated as a potential therapeutic approach in neurodegenerative diseases with a marked inflammatory component.
Alzheimer's disease (AD), the most common cause of dementia associated with neurodegeneration in the elderly, is clinically characterized by a progressive memory loss and other cognitive impairments. The prevalence of AD increases exponentially with age. In aged rats, COX-1 mRNA expression is selectively increased in the hippocampus, possibly causing an increased susceptibility to neuroinflammation [68] , and COX-1-expressing microglia are found surrounding amyloid plaques in the AD brain [69] , indicating a role of this isoform in the pathophysiology of the disease. Supporting this concept, a 6-month, double-blind, placebocontrolled study with indomethacin, a preferential COX-1 inhibitor, seemed to protect AD patients from cognitive decline [70] and reduced levels of -amyloid (A ) in the hippocampus and cortex in a transgenic mouse model of AD [71] . The use of aspirin, a nonselective A 42 -lowering agent that preferentially inhibits COX-1, has been associated with a reduced risk of AD in humans [72] .
In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease (PD), in which dopaminergic neurons in the substantia nigra are selectively injured, >65% of ventral midbrain PGE 2 originated from COX-1 without any change in COX-1 expression; this indicates a predominant role of this isoform in PGE 2 synthesis during MPTP-induced neurodegeneration [73] .
In traumatic brain injury (TBI), COX-1 involvement has not been extensively studied. There are evidences of accumulation of COX-1-expressing microglia and/or macrophages at peri-lesional areas and in the developing core in patients with TBI [74] , indicating that further investigation of the potential beneficial effects of COX-1 inhibition is necessary.
Neuronal degeneration in patients with prion diseases is well documented, little is known about downstream signaling cascades to enable targeted therapeutic strategies. Coexpression of CD68 (phagocytic macrophages and microglial cells) in COX-1-expressing cells is found in areas of severe tissue damage and also around vacuoles in post-mortem brains from patients with Creutzfeldt-Jacob disease.
Therefore, activated COX-1-expressing microglia in CJD patients could account for increased production of PGE 2 and cytokines and might contribute to the complex process of neurodegeneration.
Elevated levels of PGE 2 , PGF 2 and TXB 2 have been found in the cerebrospinal fluid of patient with HIVassociated dementia and have been linked with the severity of cognitive impairment. Because COX-1 mRNA is upregulated approximately two-fold in HIV-demented compared with the non-demented patients, whereas COX-2 mRNA expression is unchanged, the increase in the PG levels is likely to be selectively mediated by COX-1 [75] . Thus, the roles of microglia and COX-1 in the host defense system against viral pathogens deserve further investigation.
In humans and in animals subjected to transient global cerebral ischemia, specific neurons degenerate following the ischemic episode [76] . In determining brain injury there is the primary involvement of COX-2-expressing neurons and the secondary involvement of COX-1-expressing microglia. Although, mice lacking COX-1 are more vulnerable to focal cerebral ischemia, probably owing to a more severe cerebral blood-flow reduction in vulnerable regions [77] , pharmacological inhibition of COX-1 potently reduced neuronal injury and oxidative stress in the hippocampus during transient global ischemia [78] . Interestingly, in human focal ischemic brains, COX-1-positive microglia accumulation was observed in peri-infarctional regions and in the developing necrotic core early after infarction [79] . Therefore, the potential therapeutic effects of COX-1 inhibition should be further investigated, particularly in the secondary post-ischemic neuroinflammatory phase.
COX-1 inhibition also seems to attenuate neuroinflammation-induced blood-brain barrier (BBB) disruption. Selective pharmacological inhibition of COX-1, but not of COX-2, reduced TNF--induced BBB disruption and free radical production [80] , and indomethacin completely blocked LPSinduced permeability changes in cultured monolayers of brain microvessel endothelial cells [81] .
In stroke, neurons which express COX-2 are directly injured, whereas COX-1-expressing microglia only contribute to the secondary neuroinflammatory response.
Very recently, in a study on electrical amygdala kindling mouse, an animal model of human temporal lobe epilepsy, it was demonstrated the involvement of activate microglial cells in hippocampus during the epileptogenesis, the kindling development and concurrent COX-1 enhancement in this region. Stage and region specific cyclooxygenase expression were identified in the kindled brain, and changes in COX-1 immunoreactive cells were found. Treatment with SC-560 (Fig. (2) ) dose-dependently delayed the advancement of seizure stage with its anti-seizure effect. Indomethacin at lower doses than SC-560 is more potent, but at higher doses all animals died. Furthermore, in vitro experiment demonstrated that SC-560 reduced also PGE 2 and 8-isoPGF 2 productions by LPS-activated microglia leading to suppress the kindling development. This result implies that COX-1 and COX-2 are involved in manifestation of epilepsy and occurs a cooperation between the two isoforms during the kindling process [82] .
COX-1 AND PRETERM LABOUR
Endogenous prostaglandins are expressed in utero and regulate spontaneous contractile activity of uterine strips isolated from non-pregnant different species as well as labour.
In the myometrium of non-pregnant pigs, COX-1 is expressed predominantly in a muscle layer-dependent manner (longitudinal muscle > circular muscle). In fact, pretreatment of uterine strips with indomethacin and more selective COX-1 inhibitors (SC-560 and FR122047) significantly reduced both the amplitude and frequency of spontaneous contraction mainly in the longitudinal muscle [83] .
COX inhibitors, are also effective as tocolytics for delaying labor in the short term. Indomethacin, most commonly used to delay labor, induces constriction of the fetal ductus arteriosus (DA) in as many as 50% of cases following maternal administration by inhibiting the synthesis of PGs important for DA dilation in utero. In utero, constriction of the DA impedes blood flow through the vessel and may result in pulmonary hypertension or heart failure in the fetus. Further, maternal administration of indomethacin during pregnancy can also increase the risk for development of patent DA in infants after birth that contributes to neonatal respiratory distress, congestive heart failure, and conditions resulting from tissue ischemia. Then, the usefulness of NSAIDs is limited, in part, by adverse effects on the fetus.
The results about the use of selective inhibitors of two COX isoform are contradictory [84] .
More recent findings proved that the treatment of pregnant mice with a selective COX-1 inhibitor delayed the initiation of full-term labor, whereas COX-2-selective inhibitors produced no effect on gestation. Furthermore, when administered near the end of gestation, the COX-2 selective inhibitors (celecoxib) induced fetal DA constriction similar to that resulting from indomethacin treatment. In contrast, the COX-1-selective inhibitor (SC-560) does not induce constriction of the fetal DA. The COX-1 inhibitor produces patent DA only in mice genetically deficient in COX-2, whereas patent DA resulting from COX-2 inhibition does not require the genetic inactivation of COX-1. Thus, COX-1 plays only a compensatory role, and COX-2 is the isoform primarily responsible for DA closure.
If the mechanisms of DA closure are conserved between species, the use of COX-2 selective inhibitors as tocolytics in women may impede normal closure of the DA after birth. Instead, COX-1 selective inhibitors may provide effective tocolysis without the adverse DA effects of nonselective or COX-2-selective inhibitors [85] .
However, according to Momma results, not only indomethacin but also aspirin, ibuprofen, rofecoxib (selective COX-2 inhibitor), SC-560 (selective COX-1 inhibitor), and ONO-208 (EP 4 receptor antagonist) delay rat neonatal ductal closure following maternal administration on day19 and day20 (rat gestation period: 21.5 days) [86] .
Many clinically questions, concerning this problem, remain unsolved. Thus, other investigations are necessary to gain insights.
COX-1 AND PAIN
An emerging series of observations suggests there are fundamental differences in spinal COX isoenzymes involved in different pain states: postoperative, inflammatory and neuropathic. Neuropathic pain is a physically and emotionally debilitating condition for which pharmacological treatment is often inadequate. The mechanisms that underlie neuropathic pain are poorly understood, but several animal models have been developed to probe these mechanisms and also to clarify the role exerted by COX-1 [87] , taking into account that a dominant, perhaps exclusive, role for spinal COX-2 occurs with peripheral inflammation [24] .
Postoperative pain is a common form of acute pain. Its relief improves patient satisfaction and may decrease morbidity and reduce mortality. In a paw incision model, mechanical hypersensitivity to stimuli and non-evoked pain behaviour parallel the phenomena of incident and rest pain in patients. After tissue damage, dorsal horn neurons in the spinal cord as well as peripheral nociceptors are sensitized, and both spinal and peripheral sensitization processes are thought to be important in the development and maintenance of mechanical hypersensitivity [87] .
Pharmacological studies of spinal sensitization using intrathecal drug delivery indicate that this hypersensitivity results in part from a complex cascade starting with the activation of spinal neurokinin-1 and N-methyl-D-aspartate (NMDA) receptors secondary to the spinal release of substance P and glutamate. Among several elements, this cascade activates spinal phospholipases and generates prostanoids by spinal COX activity [88] , leading to spinal prostanoid release [89] . Both COX-1 and COX-2, are constitutively expressed in the spinal cord [89, 90] . In particulary, COX-1-immunoreactive cells are evenly distributed in both the gray and white matter in mouse spinal cord and exist in the gracile nucleus.
The hypersensitivity induced by paw incision is reduced by intrathecal ketorolac (COX-1 preferring inhibitor) and SC-560 (COX-1 selective inhibitor), but not NS-398 (COX-2 selective inhibitor), in a dose-dependent manner, when administrated on the first postoperative day. SC-560 has no effect on intrathecal substance P-induced thermal hyperalgesia [91] or in the formalin test [92] , further under-scoring the unique pharmacology of postoperative pain.
These data suggest that COX-1 may play an important role in pain processing and sensitization in spinal cord and gracile nucleus after surgery, and spinally administered specific COX-1 inhibitors may be useful to treat postoperative pain [87] .
Similar to postoperative treatment [93] , preoperative COX-1 inhibitors (ketorolac or SC-560) are analgesic in the paw intrathecal administration. Their administration 15 minutes before peripheral surgery decreases prostaglandins in the spinal cord by inhibiting the constitutive COX-1 and reduces the hypersensitivity induced by paw incision. On the contrary, NS-398 had no significant effect [93] .
Fever is a coordinated autonomic, endocrine, and behavioural response mediated by the brain in reaction to inflammatory stimuli. An essential step in transmitting the immune signal to the brain is the formation of PGE 2 , catalyzed non-differentially by constitutive COX-1 and COX-2. COX-2 is markedly induced in cells associated with the cerebral blood vessels and the leptomeninges by immune stimuli such as intravenous administration of LPS. However, the specific roles of the constitutive COX-1 and inducible COX-2 in LPS-induced fever are not well understood. Zhang et al. [94] injected LPS i.v. in combination with either a highly selective COX-1 (SC-560) or COX-2 (SC-236) inhibitor to determine the effects of each drug on the subsequent fever response and on the pattern of expression of Fos protein in the brain. The COX-2 inhibitor blocked LPS-induced fever and Fos expression in sites such as the ventromedial preoptic nucleus (VMPO) and the hypothalamic paraventricular nucleus (PVH), although Fosimmunoreactivity in the nucleus of the solitary tract (NTS), ventrolateral medulla (VLM), and parabrachial nucleus (PB) remained. In contrast, the COX-1 inhibitor resulted in a profound hypothermic response to LPS and blocked LPSinduced Fos-immunoreactivity in the PVH, PB, NTS, and VLM, although it had no effect on the VMPO. Although COX-2 plays a dominant role in mediating fever responses to i.v. LPS, at least some components of the response, including avoiding hypothermia and the induction of Fos in the NTS, VLM, PB, and PVH, appear to depend on COX-1 [95] .
COX-1 AND CANCER
Many efforts have been done to find out the possible relationship between the use of NSAIDs, the selective and non-selective inhibition of COXs, and the prevention and/or treatment of cancer.
In particular, COX-1 involvement in tumorigenesis has received less attention than COX-2. COX-1 seems to be important in oncogenesis since elevated levels of COX-1 expression have been found in prostate [96] , breast [97] , cervical [48] , ovarian [25, 98] cancer, and recently also in neck and head tumor [99] . Several studies attempted to prove COX-1 role in cancerogenesis by using selective COX-1 inhibitors have been accomplished. However, it is necessary to be highlighted that the use of a selective COX-1 inhibitor does not necessary involves mechanisms in which COXs are the target for the anticancer activity. Also because, selective COX-1 inhibitors mostly exert their anti-tumor activity in a COX-independent manner.
The possible involvement of COX in carcinogenesis was supported by the observation that, long-term users of aspirin or other (t)NSAIDs have a lower risk of colorectal cancer adenomatous polyps. Further, in most cancer cell lines, COX expression seems to indicate sensitivity to aspirin, while the esophageal cancer cell line (TE-1) which does not express COX-1 or COX-2, showed a 50% decrease in viable cell numbers after 7-days treatment with aspirin, whereas another esophageal cancer cell line (TE-3), which express both COX-1 and COX-2, was relatively resistant to aspirin treatment, thus suggesting a possible COX-independent antitumor activity [100] .
Prostaglandin biosynthesis and cell growth control are strictly linked: some transformed cell lines synthesize higher amounts of prostaglandins than their non-transformed counter parts and prostaglandin biosynthesis is stimulated by treatment of these cells by growth factors. A central role in carcinogenesis is assolved by PGE 2 , which has been shown to stimulate gene transcription [101] , influences mitogenesis of normal human bone cells [102] , and promotes growth and metastasis of tumors [103] . Both COX isoforms contribute to PGE 2 production, even though it seems to be COX-1 the major source of PGE 2 in normal tissue. In the case of cervical carcinomas [48] , COX-1 overexpression has been associated with the induction of angiogenic factors like vascular endothelial growth factor, basic fibroblast growth factor, angiopoietin-1 and angiopoietin-2.
The biological actions of PGE 2 have been attributed to its interaction with the four PGE 2 receptor subtypes (EP 1 , EP 2 , EP 3 , and EP 4 ). In particular, at least in intestinal carcinogenesis a genetic and/or pharmacologic approaches revealed that PGE 2 is involved in through its binding to the receptor subtypes EP 1 [104] , EP 2 [105] and EP 4 [106] .
The EP 1 receptor activates phospholipase C and the mobilization of the inositol triphosphate; the EP 2 and EP 4 receptors are coupled to the adenylate cyclase and activate the cAMP/protein kinase A pathway, and the EP 3 receptor inhibits adenylate cyclase and activates the phospholipase C.
In addition, it is well known that the development of malignant tumors is associated with mutations in oncogenes and tumor suppressor genes. The cyclooxygenase pathway of AA metabolism is also responsible for generation of malondialdehyde (MDA) (Fig. (1) ), a direct-acting mutagen [107] . MDA is produced by enzymatic and non-enzymatic breakdown of PGH 2 . The thromboxane synthase is particularly active at MDA production; approximately, 50% of the PGH 2 that interacts with TXA 2 synthase is converted to MDA. Nearly 100% yield is obtained when endoperoxides derived from other fatty acids react with TXA 2 synthase [108] (Fig.  (1) ).
Another source of MDA is lipid peroxidation. MDA production via the cyclooxygenase pathway is inhibited by aspirin, whereas production via lipid peroxidation is not. Thus, MDA is an endogenous mutagen and carcinogen produced in eicosanoid-producing tissues, particularly those with high levels of TXA 2 synthase [109] .
Moreover, the peroxidase activity of COX catalyzes the oxidation of a wide range of xenobiotics, including several classes of chemical and dietary pro-carcinogens. Aspirin inhibits these oxidations by preventing cyclooxygenasecatalyzed generation of the hydroperoxide substrate for the peroxidase [109] .
Specifically, in intestinal tumorigenesis, COX-1 exerts its effects both at an early and later stages in tumor development. In support of an early role for COX-1, there are some studies indicating that COX-1 metabolically activates procarcinogens to mutagenic intermediates [109] , and that aspirin inhibits this metabolic activation. In fact, aspirin administered at the time of 1,2-dimethylhydrazine (which induces oxidative DNA damage and pre-cancerous lesion formation in colon) treatment reduces intestinal tumorigenesis by 60%, whereas little effect on tumorigenesis was observed starting aspirin administration after the 1,2-dimethylhydrazine.
Besides, in an experimental model of human ovarian cancer (SKOV-3 cell line) [110] , SC-560 was found to be more potent in inhibiting tumor growth than ibuprofen. Furthermore, when administered together, SC-560 and ibuprofen, resulted in a synergistic antitumor effect when compared with treatment with the same doses of either SC-560 or ibuprofen alone [111, 112] . These results strongly support the consideration and development of protocols to evaluate the preclinical efficacy of combining COX-1 inhibitor with non selective COX inhibitor therapy [113] .
Tumor growth and metastasis require angiogenesis [114] . Ovarian cancer growth is angiogenesis-dependent [115, 116] , and the detection of the secretion of proangiogenic growth factors such as VEGF is of prognostic value [117] [118] [119] [120] . On the basis of the role of COX in angiogenesis and remarkable efficacy observed by inhibitors of this pathway in animal model, it has been postulated that inhibition of COX should produce antiangiogenic and antitumor results in the preclinic. Selective or non selective COX inhibitors were used to discriminate between COX-1-and COX-2-derived PGE 2 production after the end of treatment period. COX-1 inhibitor SC-560, as well as non-selective COX inhibitor ibuprofen, significantly blocked PGE 2 and VEGF release, indicating that both enzymes participate in PGE 2 production, probably to a different extent. COX-1 expression can be induced in vitro by VEGF [121] , AA, and PGE 2 [122, 123] . PGE 2 has been shown to promote growth and metastasis of tumors [102] by inducing the angiogenesis necessary to supply oxygen and nutrients to tumors [124, 125] . Gupta et al. [25] found that PGE 2 positively regulates VEGF production in ovarian epithelial cells. These data suggest that COX enzymes and/or their products may function in promoting and maintaining the neoplastic state. There is increased evidence that PGE 2 contributes to tumor progression also by promoting tumor angiogenesis, this effect is mediated, at least in part, by modulation of VEGF [126] . Thus, the ability of the COX-1 inhibitor SC-560 to limit tumor growth may be by an indirect effect on tumor angiogenesis. No lesions of the stomach or small intestine were observed in any of the groups treated with SC-560.
COX-1 AND GASTROINTESTINAL TOXICITY
NSAIDs are drugs that inhibit COX activity with a different COX-1/COX-2 selectivity. The inhibition of COX underlines the gastrointestinal toxicity caused by (t)NSAIDs.
Stomach irritation is the major side effect of (t)NSAIDs and is thought to be caused by inhibition of COX-1. Vane et al. proposed that COX-1 inhibition is the ringleader in the mechanism of gastric ulcer formation induced by (t)NSAIDs [127, 128] , because PGs are thought to be important for the protection of gastric mucosa and the expression level of COX-1 in gastrointestinal tract is much higher than that of COX-2. Therefore, in the development of (t)NSAIDs, it has been considered desiderable to minimize COX-1 inhibition [5, 129] . Nevertheless, it should be emphasized that there is no evidence of COX-1 selective inhibition being the cause of gastric damage. Langenbach et al. reported that COX-1 knockout mice do not spontaneously develop gastric lesion, as further evidence that inhibition of COX-1 alone is not sufficient to induce gastric damage [21] . Moreover, Wallace et al. reported that gastric ulcers are not formed by COX-1 selective inhibition [130] . According to their report, a COX-1 selective inhibitor, SC-560 [131] , and a COX-2 selective inhibitor celecoxib [132] , does not cause gastric damage when independently administered to rats, whereas simultaneous administration of both inhibitors results in the formation of gastric ulcers, These findings were explained by Tanaka et al. [133] who proven that COX-1 inhibition upregulates COX-2 expression resulting in the production of PGE 2 to a level necessary for mucosal integrity. These results suggest that the formation of gastric ulcers is not caused solely by COX-1 inhibition.
CYCLOOXYGENASE (COX) ENZYME: STRUC-TURE, ACTIVE SITE AND CATALYSIS
COX-1 and COX-2 isoforms share 60-65% sequence identity within species and about 85-90% sequence identity among different species [134] .
They are bifunctional enzymes that carry out two sequential reactions in spatially distinct but mechanistically coupled active sites: the bis-oxygenation of AA to prostaglandin G 2 (PGG 2 ) and the reduction of PGG 2 to PGH 2 . Arachidonic acid oxygenation occurs in the cyclooxygenase active site, and PGG 2 reduction occurs in the peroxidase active site. PGH 2 diffuses from the COX proteins (anchored on the endoplasmic reticulum membrane) to be transformed by different tissue-specific synthases to prostaglandins (PGE 2 , PGD 2 , PGF 2 , PGI 2 ) and thromboxane A 2 (TXA 2 ) (Fig. (1) ).
COX-1 and COX-2 are homodimers of 70 kDa subunits and dimerization is required for structural integrity and catalytic activity [135] .
Very recently, it has been reported that COXs function as conformational heterodimers during catalysis of oxygenation reaction of fatty acids. It seems that the fatty acids bound to both COX active sites, as proven in the case of COX-2. Initially, one fatty acid binds with high affinity to one COX active site of an unoccupied homodimer. This monomer becomes an allosteric monomer, and it causes the partner monomer to become the catalytic monomer that mediates AA oxygenation. In addition, COX-1 seems to operate efficiently on AA in the "early phase" (high cellular AA concentration) but is inhibited by other, competing fatty acids in the "late phase" (low cellular AA concentration). In contrast, COX-2 catalyzes AA oxygenation in the "late phase" because COX-2 oxygenates AA even in the presence of relatively high concentrations of other fatty acids [136] .
Each monomer contains a cyclooxygenase and a peroxidase active site and consists of three structural domains: a short N-terminal epidermal growth factor domain, a membrane binding domain, and a large, globular C-terminal catalytic domain [137] [138] [139] .
The catalytic domain constitutes the majority of the COX monomer and is the site of substrate binding and NSAID action.
The entrance to the COX active site occurs at the base of the membrane binding domain and leads to a long hydrophobic channel that extends deep into the interior of the catalytic domain [137] .
The COX channel narrows at the interface between the membrane binding domain and the catalytic domain to form a constriction composed of three residues (Arg-120, Tyr-355, and Glu-524) that separates the "lobby" from the active site.
The COX-1 and COX-2 active sites are very similar but differ for the presence of a side pocket in COX-2 located Fig. (5) . Solvent accessible surfaces in COX-1 and COX-2 [140] .
above the Arg-120/Tyr-355/Glu-524 constriction. This COX-2 side pocket is bordered by Val-523 (Ile in COX-1) and contains a conserved Arg-513 (His-513 in most COX-1) at the base of the pocket [138, 139] . The solvent accessible surface in the COX-2 active site is larger than that of COX-1 because of the one Val-523 to Ile substitution in the active site and several key substitutions in the secondary shell (Arg-513 to His and Val-434 to Ile). In addition, one of the four helixes of the membrane binding domain (helix D) is positioned differently in COX-2 and shifts the location of Arg-120 at the constriction site, allowing for a larger solvent accessible surface at the interface between the membrane binding domain and the COX active site in COX-2 ( Fig. (5) ).
Crystal structures and molecular models of ovine COX-1 and murine COX-2 complexed with AA indicate that the carboxylic acid of the substrate ion-pairs to the guanidinium group of Arg-120 and hydrogen bonds to Tyr-355. The AA aliphatic backbone projects up into the top of the cyclooxygenase active site from the hydrophobic channel and then makes a sharp bend in the vicinity of Tyr-385 [141, 142] .
The mixed structure cocrystal also yielded a conformer of AA that is bound in an inverted configuration with its carboxylate hydrogen-bonded to Tyr-385 and Ser-530. This binding conformation of AA in the active site reflects a non catalytic or inhibitory binding mode where no viable products can be produced [141, 143] . Since the discovery of the inhibition of the AA metabolism in the mechanism of action of aspirin [144] and indomethacin [145] , remarkable headway was made to understand the mechanism of NSAIDs in COX inhibition.
COX-MEDIATED CATALYSIS
Ruf and coworkers proposed a mechanism that includes the requirement of peroxido-dependent heme oxidation to initiate a mechanistically coupled oxygenase reaction in the spatially separate COX active site. The chain reactions at the catalytic sites of COX can be summarized as follows (Fig.  (6) ): the reactions start with the oxidation of iron with the formation of an heme-complex intermediate with Fe +4 and a porphyrinic radical; this radicalic intermediate estracts a hydrogen from Tyr-385 to form a radical, and porphyrine becomes neutral. This reactive intermediate (PPIX-Fe +4 = O)-Tyr radical extracts a proton to C13 of AA, to give a radical (I) that binds an oxygen molecule to form a peroxyradical intermediate (II) that cyclises, in turn, into the endoperoxyradical (III) with the two alkenyl chains in transconfiguration. The addition of a second molecule of oxygen on C15 gives PGG 2 , which is the substrate of the peroxidase reaction to form PGH 2 in the presence of reducing agents and cofactor such as uric acids, glutathione, epinephrine [146] . After PGH 2 formation, the tyrosyl radical is restored and the cyclooxygenase reaction becomes autocatalytic until radicalinduced inactivation [147] .
Up to now, many NSAIDs have been identified. They have been classified on the base of their selectivity of the inhibition of COX-1/COX-2 isoenzymes, kinetic behaviour, or chemical features.
COXs INHIBITORS

Classification of NSAIDs by Selectivity Index of COX-1/COX-2 Inhibition
A recurring classification of COX inhibitors is based on their inhibitory potency of each COX isoform and in particular their COX-1 IC 50 and COX-2 IC 50 ratio (selectivity index) [148] (Table 1) .
Based on COX-1/2 selectivities, COX inhibitors could be divided into five main groups: (1) compounds capable of producing full inhibition of both COX-1 and COX-2 with poor selectivity; (2) compounds capable of producing full inhibition of COX-1 and COX-2 with preference toward COX-2; (3) compounds that strongly inhibited COX-2 with only weak activity against COX-1; (4) compounds that strongly inhibited COX-1 with only weak activity against COX-2; and (5) compounds that appeared to be only weak inhibitors of COX-1 and COX-2. The selectivity index (SI = COX-1 IC 50 / COX-2 IC 50 ) is mostly used to compare NSAIDs behaviour against each COX isoform. Unfortunately, very often the SI value of an inhibitor depends on the assay system used to determine its IC 50 , and this makes difficult the comparison of the COX inhibition potency and selectivity of most known NSAIDs.
During the years, several in vitro assays to determine the COX activity and selectivity of inhibitors have been developed. Testing conditions are often quite different [149, 150] .
One main difference is the source of AA: endogenously released or exogenously added. Second, there are various expression systems used for gene replication of both recombinant COX-1 and COX-2 enzymes. Then, the cells transfected with the COX-1 or COX-2 gene can be of diverse origins, (i.e., insect cell lines or COS cells). Third, the assay can be carried out also in the presence of a COX-2-inducing agent (LPS or various cytokines, such as IL-1 or TNF-) or with cells that are stably transfected to constitutively express COX-2. Fourth, the incubation time with (a) drug, (b) COX-2-inducing agent, and (c) AA varies between different laboratories. Fifth, the protein concentrations in the medium can be different. This is a critical issue for NSAIDs, which are known to bind avidly to plasma proteins.
The in vitro assay system can be classified into 3 groups (Fig. (7) ):
systems using animal enzymes, animal cells, or cell lines;
2) assays using human recombinant enzymes, human cell lines, or human blood cells (mainly platelets and monocytes);
3) human cells which are target cells of antiinflammatory and adverse effects of NSAIDs including human gastric mucosa cells, chondrocytes and synoviocytes.
Such methods use not comparable experimental conditions. The enzymes used are of animal or human origin, can be native or recombinant and used either as purified enzymes, in microsomal preparations, or as whole-cells.
Recombinant enzymes are available in many laboratories because easy to use. Further, the expression systems are the same for both COX-1 and COX-2.
Methodologies that use recombinant enzymes display some drawbacks with respect to native ones: (a) COX-2 is constitutively expressed and not induced; (b) AA is exogenous; (c) cells used for gene expression are not target cells at least for NSAIDs adverse side effects, and (d) cell lines used may have different properties compared with "normal" cells.
The exact information on interaction of the drug with the enzyme free from endogenous influences (e.g. plasma protein binding, cell-cell interactions and diffusion processes) is obtainable by using isolated enzymes. However, the results Fig. (7) . Pannel describing the more diffused assays to test COX activity.
do not resemble to patho-physiological conditions and can not be traslated to the humans [151] .
One of the most used sources of COX enzymes is human blood platelets and monocytes.
The human whole-blood assay (HWBA) [152] has many advantages, as uses intact human cells. The plasma proteins present in whole blood also provide a better model of in vivo interactions in the presence of NSAIDs. In addition, whole blood used to assays COX-1 and COX-2 activity is taken from the same volunteer (or patient) at the same time, which allows a direct comparison of the results from each assay.
Finally, the assay can be performed using blood from volunteers (or patients) who have been treated previously with NSAIDs (ex vivo assay), thus allowing a comparison of the in vivo relevance of in vitro findings.
Another advantage is that AA is endogenous and at physiological concentration. As a consequence, compounds to be tested, even at high concentrations, can be examined outside the body in a physiological environment resembling most closely the in vivo conditions (e.g., temperature of 37 °C, homeostasis, all blood components are present and cell-cell interactions remain intact). On the other hand, variability of different donors has to be considered because of metabolism and different enzyme expression. One of the major disadvantages of whole blood assay is the volunteer recruitment. Besides, cell types other than platelets and monocytes, such as gastric mucosal cells and synoviocytes, would be more representative of target cells for NSAIDs therapeutic and adverse effects. [127] modified HWBA, even if the latter is still a valid method, for testing COX-2 activity, by adding the human A549 cell (carcinomic human alveolar basal epithelial cells), as an additional source of COX-2, to the human whole blood. In this case, because of the presence of a greater amount of COX-2 enzyme with respect to the use of only human whole blood, incubation time becomes the same as used for COX-1 (1h). Of interest, a number of the compounds tested were found to be more potent in the WHMA-COX-2 than HWBA-COX-2. This could be caused by the variations in either the metabolism or the plasma binding of compounds within the blood samples during the different time courses of the HWBA and WHMA. Alternatively, it could be explained by considering the different levels or sources of free AA within the cells expressing COX-2 in the two assay systems, or even to the binding characteristics of the NSAIDs to COX-2.
Another modification of HWBA implies the use of a selective COX-1 inhibitor (SC-560) and a thromboxane synthase inhibitor (CV4151). CV4151 allows for less LPS using and increases prostaglandin production. Another difference between the two assays consists in the use of Cremophor EL®-EtOH as vehicle instead of DMSO because allows to solubilize also hydrophobic compounds [151] .
Once the enzyme source and other assay determinants have been chosen according to the exigencies of the study, different detection methods (Fig. (7) ) can be suitable to test direct (RIA, EIA) and indirect (Oxygen uptake assay, Peroxidase assay) COX activity. Herein, the most common used methods to detect COXs activity are outlined. [153, 154] The oxidation of AA to PGH 2 by COX is associated with the consumption of 2 moles of oxygen per mole of product formed. The oxygen consumption profile, detected by a polarographic oxygen electrode, is characterized by a rapid, COX dependent reduction of oxygen concentration after addition of AA. The rate of reduction of oxygen concentration diminishes until all the enzyme is inactivated. This worthnoting assay allows to establish kinetic parameters for the COX isozymes (Fig. (8) ), and is widely used for quantitative comparison of the COX activity. [155] This assay measures the peroxidase catalytic activity of COX and is an indirect measure of COX activity that will be Fig. (8) . Description of oxygen-uptake method for COX activity evaluation.
COXs ACTIVITY DETECTION BY OXYGEN UPTAKE METHOD
COXs ACTIVITY DETECTION BY PEROXIDASE METHOD
very sensitive to compounds that are also co-reductans. While the cyclooxygenase initiation is dependent on peroxidase turnover, the inverse is not true: peroxidase activity can occur at/or near maximal efficiency in the absence of a functional cyclooxygenase active site. It should be also noted that the most precise enzymatic measurements made in the literature are derived from this assay, which directly quantitate the two activities of the enzyme. The peroxidase activity is assayed by utilizing N,N,N',N'-tetramethyl-p-phenylenediamine (TMPD) as a co-substrate with AA. TMPD will not turn over without the presence of a hydroperoxide substrate (PGG 2 ). TMPD oxidation is monitored spectrophotometrically at 590 nm (Fig. (9) ) [156, 157] .
COXs ACTIVITY DETECTION BY ENZYME IMMU-NOASSAY (EIA) [158]
The most used method to measure COX activity is based on the quantification of COX-mediated products (COX-p: PGF 2 , PGE 2 and TXB 2 ) by using an enzyme immunoassay (EIA) (Fig. (10) ). EIA method rapidly diffused after the development of several commercially available kits in which the antibody is coated on a multi-well plate. This assay is based on the competition between a COX-p and the relative COX-p-acetylcholinesterase (AChE) linked to a specific tracer for a limited amount of COX-p monoclonal antibody. Because the concentration of the tracer is held constant, whereas the concentration of COX-p varies, the amount of COX-p tracer that is able to bind the COX-p antibody is inversely proportional to the concentration of COX-p in the well. This complex antibody/COX-p binds to goat polyclonal anti-mouse IgG previously attached to the well. After plate washing, Ellman's reagent that contains the substrate of AChE is added to the well. The product of this enzymatic reaction has a distinct yellow colorant absorbing at = 412 nm. The intensity of this colour is proportional to the amount of COX-p. This method allows the screening of a large number of new potential inhibitors with cheap materials and in a short time (Fig. (10) ). [159, 10] The radioimmunological assay is based on the competition between 3 H-PGE 2 or 3 H-TXB 2 and endogenous antigen for the corresponding specific antibody (Fig. (11) ). The result is the formation of an antigen-antibody complex and an amount of radiolabelled antigen free that is detected by measuring -ray. Fig. (9) . Description of peroxidase assay for COX activity evaluation.
COXs ACTIVITY DETECTION BY RADIOIMMUNO-LOGICAL ASSAY (RIA)
Fig. (10). Description of Enzyme Immuno Assay (EIA).
This assay allows to measure even small amounts of prostanoids, but it is particularly more expensive than other detection systems and provides radioactive pollutant wastes.
In conclusion, all of the above mentioned methods are usefull to test COX activity. The choice of the more suitable assay depends on many factors such as performing troughoutput screening or to determine kinetic parameters, to collect information on the inhibitor binding mode to the enzyme, to have a model resembling human pathophysiological conditions, to reduce time and optimize costs.
KINETIC MODE OF COX INHIBITION
From a kinetic point of view, COX inhibition consists of multiple equilibria established between free enzyme, inhibitor, and two or three enzyme-inhibitor complexes. All COX inhibitors can be grouped on the basis of which steps or series of steps are observed in their inhibitory mechanisms.
Aspirin (2-acetoxybenzoic acid) is the only clinically used inhibitor that irreversibly inactivates COX-1 and COX-2 through time-dependent, covalent modification of the COX active site. Aspirin acetylates Serine 530, in fact, S530A mutant is resistant to aspirin acetylation and inactivation [160, 161] . The clinical use of aspirin, as inhibitor of platelet COX-1, could be suppressed by co-aministration of NSAIDs (e.g., ibuprofen, naproxen) [162] . Very recently, it has been reported, based on crystallographic data, that celecoxib binds to the COX active site of one monomer of COX-1 homodimer. As a consequence, aspirin binding to the partner COX-1 monomer is altered so as to slow the rate of acetylation of the enzyme. In marked contrast, binding of celecoxib to one monomer of COX-1 does not affect (being a highly selective COX-2 inhibitor) the manner in which AA binds and is oxygenated within the COX active site of the partner monomer [163] .
All other COX inhibitors, whether non selective or COX-2 selective, associate with the protein in a noncovalent manner. The most potent COX inhibitors are slow, tight binding inhibitors that form very stable binary complexes. In some cases, the dissociation rates of enzyme-inhibitor complexes are so slow that the inhibitors appear to be functionally irreversible.
The structural requirements for the time-dependent inhibition of prostaglandin biosynthesis by different antiinflammatory drugs were first evaluated by Rome and Lands [164] . In their study, ibuprofen (2-[4-(2-methylpropyl) phenyl]propanoic acid) and mefenamic acid [2-(2,3-dimethylphenyl)aminobenzoic acid] display competitive and rapidly reversibile inhibition of the COX activity of sheep seminal vesicle preparations that is characterized by a singlestep mechanism (I). On the other hand, flurbiprofen [2-(3-fluoro-4-phenylphenyl)propanoic acid] and meclofenamic acid [2-(2,6-dichloro-3-methylphenyl)aminobenzoic acid] exhibit time-dependent, functionally irreversibile inhibition of COX activity that displays a two-step mechanism [140] .
Rome and Lands developed a kinetic model to explain their observations in which there is an initial rapid, reversible binding of the inhibitor to the enzyme characterized by a dissociation constant K I , followed by an essentially irreversible time-dependent change in the enzyme-inhibitor complex characterized by the rate constant k inact (II):
In the decades that followed, many other COX inhibitors were investigated for their kinetic mode(s) of inhibition with most NSAIDs and selective COX-2 inhibitors displaying time-dependent inhibition with either a two-step mechanism (e.g., diclofenac (2-[(2,6-dichlorophenyl)amino]benzeneacetic acid) and indomethacin) [164] (III),
or a three-step (diarylheterocycles like celecoxib) mechanism (IV) [165] .
IV
As observed for flurbiprofen, these inhibitors interact with COX initially through a rapid association that is then followed by one or more slow, time-dependent steps, which leads to a much more tightly bound complex. The magnitude of the rate constants for the reverse reactions are the major determinants of the potency and selectivity of COX inhibition.
In summary, two distinct kinetic mechanisms for the inhibition of COX-2 have been identified. Inhibitors such as NS-398, flurbiprofen, indomethacin and meclofenamic acid act in a time-dependent manner resulting in the formation of an irreversibly inhibited enzyme species having a small residual activity. Time-independent inhibition of COX-2 is Fig. (11) . Description of Radioimmunological Assay (RIA).
observed with flufenamic acid, consistent with reversible complex formation. NS-398 acts in a time-independent manner towards COX-1. It appears that the high degree of selectivity exhibited by this compound is the result of the two different mechanisms by which it interacts with each isoform [166] .
Another classification of NSAIDs takes into account the chemical features of the inhibitors.
CHEMICAL CLASSIFICATION OF NON-STER-OIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs)
NSAIDs can be grouped ( Table 2) , from a chemical point of view, into three main classes: (1) carboxylic acids, (2) phenazones (pyrazolones, oxicams) and (3) non-acidic compounds. To "carboxylic acids" class belong salicylic acids and esters, acetic acids, propionic acids, and fenamic acids.
Similarly to arachidonic acid, most of NSAIDs of "carboxylic acids" class interacts with COX-1, forming a salt bridge [140] with Arg-120 of the hydrophobic channel (Fig.  (12) ), which orientates the aromatic portion of these molecules in the direction of the Tyr-385 at cyclooxygenase catalytic site (Fig. (5) ) [137, 139] , that in turn is also essential for irreversible inhibition of COX-1 and COX-2 by aspirin. Aspirin covalently modifies both COX-1 and COX-2 through acetylation of Ser-530 and is 10-100 fold more potent against COX-1 than against COX-2 [168, 169] . The product of the reaction, salicylic acid, is also bound in the active site, which provides an explanation for the selective delivery of the Table 2 (Fig. (13) Fig. (12) . Schematic shape of COX-1 and COX-2 active site [167] . Fig. (13) . Chemical structure of some NSAIDs belonging to the "carboxylic acid" class listed in Table 2 .
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acetyl group to Ser-530. The salicylate carboxyl group ionpairs to Arg-120, which is located immediately below Ser-530. Mutation of Arg-120 to Gln or Ala eliminates ionpairing and hydrogen bonding interactions with the salicylate group and significantly reduces aspirin acetylation of Ser-530 [170] . The acetyl group on Ser-530 projects into the active site immediately below Tyr-385, closing off the top of the channel and blocking the access of the AA to the catalytic tyrosyl radical (Figs. (5) and (6)). The tyrosyl radical is generated from the peroxidase reaction and initiates the cyclooxygenase reaction, which then becomes autocatalytic in the presence of the AA, until radical-induced inactivation occurs.
Salicylic acid is a weak direct inhibitor. In the COX active site, its conversion into 2,3-and 2,5-dihydroxysalicylic acid [171] by O 2 · would demonstrate that its whole activity derives also from an indirect functional inhibition of COX, acting as oxyradical scavenger similarly to other phenolic compounds [172] with anti-inflammatory and/or antirheumatic properties such as eugenol, resveratrol and guaiacol.
X-ray crystallography of COX-inhibitor complexes and site directed mutagenesis studies have helped to elucidate the molecular bases behind the selective inhibition of some arylpropionic and arylacetic acid inhibitors.
Most crystal structures of COX enzymes with carboxylic acid-containing NSAIDs (i.e., ibuprofen, mefenamic acid, flurbiprofen, meclofenamic acid, indomethacin, aclofenac) show the inhibitors positioned with their carboxylates coordinated to Arg-120 and their aromatic groups projecting up into the cyclooxygenase active site.
Unlike most other NSAIDs with carboxylic acid moieties (i.e., diclofenac, lumiracoxib), neither Tyr-355 nor Arg-120 makes contact with the inhibitor, which binds in an inverted conformation with its carboxylate coordinated to Ser-530 and Tyr-385 [143] .
Recently, a crystal structure of mCOX-2 with lumiracoxib (selective COX-2 inhibitor), a phenylacetic acid derivative of diclofenac, was solved and shown that lumiracoxib binds in the COX active site in an inverted orientation [140] , as also diclofenac makes. The methyl group on the phenylacetic acid ring of lumiracoxib projects into a small groove near Leu-384 in the COX-2 active site (Fig. (12) ) [140] . When lumiracoxib is modeled into COX-1, the methyl group of the inhibitor clashes with the side chain of Leu-384, suggesting a possible rationale for its COX-2 selectivity [140, 173] .
Pyrazolones (phenylbutazone, phenazone, aminophenazone, dipyrone) (Fig. (14) ), are antipyretic-analgesic compounds; they are weak anti-inflammatory drugs and poor inhibitors of the cyclooxygenase, and their effective inhibition mechanism is probably due to their scanvenging activity of neutrophil generated reactive oxygen species (ROS). They are atypical NSAIDs, which effects depend on peroxide tone and are also defined as peroxide sensitive analgesic and antipyretic drugs (PSAADs) [174] .
Dipyrone behaves as a potent analgesic drug through the inhibition of COX.
In contrast to traditional COX inhibitors, such as aspirinlike drugs, dipyrone has a low gastrointestinal toxicity and no anti-inflammatory effect, indicating a probable different mode of action.
Further, dipyrone active metabolites, such as 4-methylamino-antipyrine and amino-antipyrine, inhibit COX activity by sequestering radicals which initiate COX catalytic activity or through the reduction of the oxidative states of the COX proteins [175] .
Oxicams (piroxicam, tenoxicam, meloxicam) [127] still have acid properties because of their enolic structure (Fig.  (15) ), and as demonstrated by mutagenesis experiments, are also able to form hydrogen-bonds with Arg-120, Tyr-355, and Ser-530 [176] . They usually have a much longer plasma half-life than other NSAIDs.
Diarylheterocycles such as valdecoxib, celecoxib, DuP-697, rofecoxib, (Fig. (16) ) and many other structurally simi- Fig. (14) . NSAIDs belonging to the pyrazolone group ( Table 2 ). (15) . NSAIDs belonging to the oxicam group ( Table 2) . lar compounds were found to be preferentially or highly selective COX-2 inhibitors. They display a competitive reversible time-dependent kinetics.
Many attempts have been made to convert non selective NSAIDs into COX-2 selective inhibitors (Fig. (12) ), and not vice versa NSAIDs into COX-1 [137, 139, [177] [178] [179] [180] [181] [182] [183] . For the same scope, comparative molecular field analysis [184] , and comparative molecular similarity indices analysis were also performed on different groups of compounds enclosed 114 analogues of 1,2-diarylimidazole to optimize their COX-2 selective anti-inflammatory activities. These studies produced models with high correlation coefficients and good predictive abilities. Docking studies into the active sites of both COX-1 and COX-2 were also carried out to analyze the enzyme-inhibitor interactions that confer selectivity for COX-2.
In summary, the general structure of COX-2 selective inhibitors (coxibs) [185] consists of a central ring bearing two aryl or heteroaryl groups, in which one of the two aryls has a sufamoyl (-SO 2 NH 2 ) or methylsulfonyl group (-SO 2 CH 3 ).
Sequence alignments between COX-1 and COX-2 and homology modeling of human COX-2 based on the existing ovine COX-1 crystal structure [137] identified Val-523 as the only residue in the main channel of the COX-2 active site that is not conserved in COX-1 [186, 187] .
The V523I mutation abolishes the selectivity of all the inhibitors for COX-2, whereas traditional NSAIDs like indomethacin show no change in their selectivity profile.
The first crystal structure of hCOX-2 shows that there is an overall difference in the size and shape of the COX-2 active site compared to that of COX-1 (Figs. (5) and (12)) [140] . The nearly 25% larger active site of COX-2 is accounted for the single Val-523 substitution (Ile in COX-1) in the active site and by the Arg-513 and Val-434 substitutions (His-513 and Ile-434 in COX-1) in the secondary shell.
Extensive structure-activity studies demonstrated that the presence of a 4-sulfamoyl or 4-methylsulfonyl group on the phenyl ring of the inhibitor provides COX-2 selectivity, and that no other substitution is tolerated [188, 189] . From additional structure-activity analysis, it becomes clear that the fundamental factors responsible for the potent and selective inhibition of COX-2 include (1) two aromatic rings at adjacent positions of a central ring scaffold and (2) the presence of a sulfamoyl or methylsulfonyl group on one of the phenyl rings [190] . Further, it was also found that (a) within the 3,4-diarylisoxazole class (valdecoxib and its analogues) of COX-2 inhibitors, the 4-sulfamoylphenyl group is essential for good COX-2 inhibitory potency, (b) lacking the sulfamoyl moiety reverses the COX-2 selectivity in favour of COX-1 [191] , (c) the reduced side pocket volume of COX-1 (Val-523 to Ile) is not the only source of diarylheterocycle COX-2 inhibitors selectivity [192] , (d) electronic properties of the two aryls are also striking features for COX-1 selectivity.
In a very limited number of cases, from these diarylheterocycles, COX-1 selective inhibitors could be derived by removing the sulfamoyl or methylsulfonyl group [191] .
Actually, a very few COX-1 selective inhibitors are known. They can be grouped, based on chemical features, into five classes such as (1) (Fig. (2) ) was identified by Tanaka et al. [193] as a potent inhibitor of malondialdehyde formation (IC 50 = 0.088 μM) (Fig. (1) ).
COX inhibitor activity of FR122047 was measured (IC 50 = 0.028 and 65 μM for COX-1 and COX-2, respectively) in chinese hamster ovary (CHO) cells expressing the recombinant hCOX-1 and hCOX-2. Its inhibitory potency is 2321-fold in favour of COX-1.
Using an ex vivo rat whole blood assay, FR122047 (0.032 -3.2 mg/kg) inhibits COX-1-derived TXB 2 production with ED 50 = 0.059 mg/kg, indicating that it is orally active. In fact, oral administration of FR122047 showed a dose-dependent anti-inflammatory effect in rat type II collagen-induced arthritis with ED 50 value of 0.56 mg/kg [194] .
Tanaka et al. also evaluated ulcerogenic activity of FR122047 according to the presumptions that compounds with a basic function like FR122047 are less likely to cause gastric damage because they exist predominantly in an ionized, lipid-insoluble form and are localized in platelets after oral administration. In fact, as expected, FR122047 has not ulcerogenic activity even at 100 mg/kg in rats, which is 70- Table 2 .
fold higher than the effective dose, while aspirin damages the stomach at its effective doses (the safety margin of aspirin in rats is only 1.2) [193] .
An exhaustive structure-activity relationship study focused on COX selectivity could be useful to identify the structural determinants responsible for its selectivity.
Mofezolac, 2-[3,4-bis(4-methoxyphenyl)-5-isoxazolyl] acetic acid (Fig. (2) ) [195] , is a potent and highly preferential inhibitor of COX-1. Its COX-1 and COX-2 IC 50 values are 0.0014 and 0.44 μM, respectively [196, 197] (EIA measurement of PGE 2 produced from ovine seminal vescicles COX-1 and placental COX-2). A rationale of its COX-1 activity and selectivity has not been proposed yet.
Mofezolac, from a chemical point of view, has two methoxyphenyls, as FR122047, linked to a central heterocycle (isoxazole for mofezolac and thiazole for FR122047).
Mofezolac has been marketed only in Japan as analgesic drug (Disopain ® ), for its rapid pain-relieving activity in acute inflammation.
Administration of mofezolac does not produce any gross changes in the liver, kidneys, stomach, intestines and lungs of the mice. In the stomach, long-term administration of mofezolac to rat neither bleeding nor gastritis is observed microscopically [197] .
In normal intestine tissue, COX-1 is the major source of PGE 2 , whereas both COX-1 and COX-2 contribute to PGE 2 production in intestinal polyps development in mice. Mofezolac has been also found to reduce the number of aberrant crypt foci in rat intestinal polyposis models [197] . Hence, it could be investigated as useful drug for chemoprevention of colon carcinogenesis.
In fact, Chulada et al. [14] , by genetic disrupting of the COX-1 gene, demonstrated that in intestinal tumorigenesis in Min mice, the COX-1 involvement is comparable with that of the COX-2 isoform and the number of intestinal polyps decreased by around 80%. Such results were later confirmed by Wakabayashi who provided clear evidence that mofezolac suppresses both AOM (azoxymethane)-induced ACF (aberrant crypt foci) formation in rats and spontaneous intestinal polyp development in (adenomatous polyposis coli) Apc knock-out mice in a dose-dependent manner [197] .
SC-560,
5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole (Fig. (2) ) is a member of the diarylheterocycle class of COX inhibitors but differently from other members of this class, it is a selective inhibitor of COX-1. Unlike similar compounds such as celecoxib, SC-560 is a time-dependent COX-1 inhibitor [198] .
It was uncovered together with celecoxib and a number of other COX-1 potent inhibitors from Penning and Talley [132] during the development of 1,5-diarylpyrazoles as COX-2 selective inhibitors. Penning and Talley studied the structure-activity relationships of these compounds with the aim to define the structural determinants for selective COX-2 inhibition.
COX-1 inhibition increases by modifying the chemical structure of 1 (Fig. (17) ) as follows: sufamoylphenyl)-and 1-[4-(methylsulphonyl)phenyl] pyrazole derivatives gave compounds (celecoxib and 2) more active against recombinant hCOX-1; differently, the addition of a halogen, methyl or methoxy (i. e., 3) groups in to the para EDG group reduced their COX-1 inhibitory potency (Fig. (17) ).
some carbocycles and heterocycles such as dihydrobenzofuranyl (4), thienyl (5) on 5-position of some 1-(4-sufamoylphenyl)pyrazoles improved COX-1 inhibition activity compared to 1, and the same results were obtained also with the introduction of a NH 2 (6) or fluorine (7) on C4 of pyrazole (Fig. (18) ):
most of the 3-(trifluoromethyl)-1,5-diarylpyrazoles lacking the sulphamoyl moiety become COX-1 inhibitors. In particular, the symmetrical not substituted (8), 4-chlorophenyl (9) and 4-methoxyphenyl (10) analogues of 1 were potent and selective COX-1 inhibitors. Among the unsymmetrically disubstituted 3-(trifluoromethyl)-1,5-diarylpyrazoles (11, SC-560 and 12), SC-560 (Fig. (2) ) and its isomer 11 have diverse COX inhibitory activity, whereas the 3-(trifluoromethyl)-5-(4-fluorophenyl)-1-(4-nitrophenyl)-1H-pyrazole 12 is a less potent but very selective COX-1 inhibitor (Fig. (19) ).
SC-560 is the COX-1 inhibitor most used as a pharmacological tool [131] , even if its overall mechanism of action has not been elucidated yet. SC-560 does not inhibit the biosynthesis of COX-2-generated prostaglandins in rat LPSinduced air-pouch model where it was found to be ineffective in the treatment of inflammation [199] . On the contrary, SC-560 selectively inhibited COX-1 both in vitro and in vivo in standard models of inflammation and pain, such as carrageenan footpad oedema [131] .
Moreover, it was found that SC-560 has comparable effects to aspirin on whole-blood thromboxane synthesis, which is an index of COX-1 inhibitory activity [200] .
In neuroinflammation studies, it was found that like in the COX-1-null mice, the selective inhibition of COX-1 by SC-560 in wild-type mice, reduced TNF--induced blood brain barrier disruption and free radical production by decreasing brain levels of PGE 2 , PGD 2 , PGF 2 and TXB 2 and the expression of pro-inflammatory cytokines and chemokines [201] .
Like sulindac sulfide, SC-560 acts as a chemopreventive in human colorectal carcinoma HCT-116 cells, because induces apoptosis and inhibits cell proliferation and cell growth by altering gene expression [202] . SC-560, induces a dose-dependent growth inhibition and cell cycle arrest at the G1 phase in human colon and lung carcinoma cell lines in a cyclooxygenase-independent manner. SC-560 acts as a reactive oxygen species generator to suppress the growth of breast and lung cancer cells.
Replacement of the SO 2 NH 2 moiety of celecoxib (Fig.  (17) ) by a SO 2 N 3 group gave the 4-[5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonylazide (13) (Fig. (20) ) that selectively inhibits COX-1 (COX-1 IC 50 = 3.3 μM; COX-2 IC 50 > 100 μM). Docking experiments indicate that the dipolar N 3 moiety of the SO 2 N 3 substituent interacts with Arg-120 at the mouth of the primary binding site, like the CO 2 H group of NSAIDs. By shifting SO 2 N 3 substituent from the p-to the m-position of the N 1 -phenyl ring affords 14 that may result in a more suitable orientation within the COX-2 binding side providing selective COX-2 inhibition. Introduction of a p-OMe substituent on the C5 phenyl ring abolished both COX-1 and COX-2 inhibitory activity (15) . In addition, compound 16 having a 5-(4-fluorophenyl) at C5 (17), and reversed the celecoxib selectivity in favour of COX-1 (IC 50 = 0.59 μM) with respect to COX-2 (IC 50 = 178.81 μM) [203] .
P6, 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (Fig. (2) ) is a 3,4-diarylisoxazole analogue of valdecoxib [4-(5-methyl-3-phenylisoxazol-4-yl)-benzensulfonamide, (Fig.  (16) )] (COX-1 IC 50 = 26 μM, COX-2 IC 50 = 0.87 μM, by HWBA), synthesized by (a) 1,3-dipolar cycloaddition of (5-chlorofuran-2-yl)nitrile oxide and the lithium enolate of phenylacetone, obtained by metallation with LDA at 0°C, and (b) the dehydration-aromatization reaction under basic (or acid) conditions of the 3-(5-chlorofuran-2-yl)-5-hydroxy-5-methyl-4-phenyl-2-isoxazoline intermediate. Its COX-1/COX-2 selectivity was evaluated in vitro by the Human Whole Blood Assay [191] .
To investigate the effect of molecular structure modification on COX-1/COX-2 inhibitory activity, a set of substituted diarylisoxazoles was synthesized.
Removal of sulfamoyl moiety from valdecoxib gave 5-methyl-3,4-diphenylisoxazole (P10) (Fig. (21) ) with a COX-1 IC 50 value 300-fold lower than that of valdecoxib; the elongation of 5-methyl side chain in P10 to P9 (5-ethyl-3,4-diphenylisoxazole) slightly decreases the COX-1 IC 50 from 0.09 to 0.05 M, about two-fold than P10 and 540-fold lower than valdecoxib. Introduction of a substituted heterocycle on the C3 of the isoxazole ring gave P6 (Fig. (2) ) that inhibits platelet COX-1 activity with an IC 50 = 0.5 M, whereas does not inhibit monocyte COX-2 activity at all at 100 M final concentration, and with a COX-2/COX-1 selectivity index >200 [191, 204] . Further, the introduction of EDG and EWG bond to the 3-phenyl provides compounds with lower IC 50 values towards monocyte COX-2 and platelet COX-1 activities >100 μM, which structure-activity relationships suggest that also (a) within the 3,4-diarylisoxazole class (valdecoxib and its analogues) of COX-2 inhibitors, the p-sulfamoylphenyl group is essential for good COX-2 inhibitory potency, (b) the lack of the sulfamoyl moiety increases the COX-1 inhibitory selectivity and potency.
Thiophene DuP-697 (Fig. (16) ), a moderately selective COX-2 inhibitor, has been used as "lead" compound for the preparation of a series of 2,3-diarylthiophenes ( Fig. (22) ), which hCOX-1 and hCOX-2 inhibitory activity was evaluated by measuring PGE 2 production by EIA.
The replacement of the methylsulfonyl group at DuP-697 with groups such as carboxyamide (18) , carbonyl (19 and 20) , carboxymethyl (21), cyano (22) , oxymethylen (23) , thiomethoxy (24) and methylsulfoxide (25) provides compounds endowed with remarkable selectivity in favour of COX-1. This finding confirms, once again, the importance of the lack of methylsulfonyl group to achieve COX-1 preferential inhibition [192] .
Anilides
Benzanilides
Indomethacin, (Fig. (13, 23) ) has been selected as a "model" compound for a structure-activity relationship study, because it possesses a more potent inhibitory activity against COX-1 than against COX-2 (IC 50 = 0.013 and 1 μM by HWBA for COX-1 and COX-2, respectively) [205, 206] . Indomethacin interacts differently with the two COX isoforms [139, 207] . It interacts with COX-1 in s-cis or s-trans conformation, with the aromatic rings being located in the same or opposite direction at the amide bond, respectively, whereas the interaction with COX-2 involves only the s-cis form. Since the importance of s-trans conformation for indomethacin-COX-1 interaction, a large number of substituted benzanilide-derivatives (26, Fig. (23) ) were used for a structure-activity relationship study [208] , as it is well known the s-trans conformation of that compounds exist both in solution and in the solid state [209, 210] .
A preliminary screening performed on a large number of benzanilides, at 100 μM final concentration, suggests that although the indomethacin, which posseses a chlorine, TFAP in which CF 3 is in m-position (35) is lower; isomers of 35 (36) (37) having the amino group in different positions of piridyl ring are inactive on both COX isoenzymes. When CF 3 and NH 2 groups are reverted (38) with respect to TFAP, COX-1 activity is recovered. When reverting the benzanilide structure of 38 to the corresponding isomer (39), the COX inhibitory activity is completely lost (Fig. (25) ).
The activity of TFAP demonstrates that the design of potent and selective COX-1 inhibitors can be based on molecules with s-trans conformation, clearly different from those of diarylheterocycles such as SC-560, FR122047, mofezolac, and P6. TFAP, as for other known COX-1 selective inhibitors, is able in vivo to cause little gastric damage in rats even at an oral dose of 300 mg/kg, though it has an analgesic effect at the lower dose of 10 mg/kg.
A summary of structure-activity relationships is depicted in Fig. (26) .
Benzenesulfonanilide
Some suitable substituted benzenesulfonanilides were found to be COX-1 selective inhibitors [211] . They are similar to diarylheterocycles being equipped with two aryls that in turn are not linked by a heterocycle ring but by a SO 2 NH unit. The overall geometry of these compounds is conserved since sulphonamide orients its substituents in a s-cis conformation [212] . Benzenesulfonanilide (40, Fig. (27) ) were also used to perform structure-activity relationship studies [213] . Therefore, a set of benzenesulfonanilides (Fig. (28) ) was screened for their inhibitory activities toward each COX isozymes assessed by colorimetric COX (ovine) inhibitory assay. Most of the compounds bearing, in different positions, a combination of substituents such as carboxyl, nitro, amino and methylsulfonamide groups is inactive at 100 M final concentration, with the exception of nitro-and aminoderivatives containing an halogen. p-Chloro derivative (41, Fig. (28) ) is more potent than the corresponding regioisomers, in which the chlorine atom is in meta or ortho position, and comparable with its Nmethyl analogue (42) that is the most hydrophobic compound in this sulfonanilide series with COX-1 IC 50 = 3.2 μM and COX-2 IC 50 > 100 μM.
N-Unsubstituted compounds were obtained by reverting the position on the sulfamoyl moiety (Fig. (28) ). They were found to be inactive towards COXs, whereas N-methyl derivatives were fair potent and selective COX-1 inhibitors (43-45).
The structure-activity relationship suggests that p-chloro, N-methylsulfonamide, and p-amino groups are important to exhibit a COX-inhibitory activity and a COX-1 isoform selectivity, as depicted in Fig. (29) .
In summary, to achieve selective COX-1 inhibition, benzenesulfonanilide inhibitors should have the following structural determinants: 1) two aryl groups s-cis linked by a SO 2 -NH unit;
2) the presence of one para-chloro or para-amino group is necessary on each aromatic ring;
3) the sulfonamide moiety should be N-methylated. The most active compounds were further investigated, and were found (a) to be competitive COX-1 inhibitors (b) to have a moderate analgesic and anti-inflammatory activity and (c) not able to induce macroscopically or histologically detectable gastric damage in rats [211] .
Arylpropionic Acids
Flurbiprofen and ibuprofen structures (Fig. (30) ) were modified to study the kinetics of COX-1-inhibition. It was found that substitution of fluorine with other halogens or other groups does not change the time-dependent inhibition mode of the 2-aryl propionic acids, because the removal of fluorine (46) from flurbiprofen or the addition of bromine (55, Fig. (30) ) to ibuprofen does not alter the inhibitory kinetic profiles [214] , although halogenation of ketoprofen (Fig. (13) ) produces ineffective compounds [215] . Conversion of the carboxylate moiety of flurbiprofen to an ester (47) or amide (48) abolishes the slow tight-binding behaviour, regardless of halogenation state, demonstrating that alteration of the carboxylic acid moiety of 2-aryl propionic acids alters the slow tight-binding kinetic. These results indicate that the neutralization of the carboxylic group leads to reversible competitive inhibitors of COX-1, that do not form an ion pair with Arg-120 in their binding mode [176] , as reported for the fenamate and indole acetic acid classes of cyclooxygenase inhibitors [178, 179, 183] .
The methyl ester of flurbiprofen (47) is a weak inhibitor that displays no time-dependence. Interestingly, the methyl ester (51) is seven-fold more potent than its fluoro-analogue. The structural basis for this is not readily apparent from the crystal structures of COX-1 bound to flurbiprofen, 46 and 47. It has recently been shown that, certain carboxylic acidcontaining NSAIDs can bind to COX in an 'upside-down' orientation, with the acidic group interacting with Ser-530, rather than Arg-120 [176] ; perhaps, in a similar manner, the loss of the fluorine atom allows 51 to flip from the expected orientation and find a more favorable binding site with its ester moiety in the upper part of the cyclooxygenase channel. All of the amide derivatives (48-50 and 52-54) examined proved to be reversible competitive inhibitors of COX-1 (Fig. (30) ), with no slow tight-binding character. Increasing substitution on the amide moiety decreased potency in the series (48-50) derived from flurbiprofen. However, the same pattern of substitution (52) (53) (54) had the opposite effect in the dehalogenated series derived from 46: potency increased with increasing steric bulk at the amide moiety.
Bromination of ibuprofen (55) improved the potency 10-fold towards COX-1. The crystal structure of ibuprofen bound to COX-1 shows that the phenyl and isobutyl groups of the inhibitor make relatively few close contacts within the active site, and that the ligand is somewhat smaller than the actual volume of the cyclooxygenase active site [216] .
Halogenation can also exert more suitable effects on NSAIDs recognition by COX, as from the comparison of compounds 48-50 and 52-54. In contrast, alteration of the carboxylic acid moiety of 2-arylpropanoic acid appears to be a dependable route to abolishing slow tight-binding behaviour. Unfortunately, no data on COX-2 inhibitory activity have been reported and so no conclusions on selectivity can be highlighted. Fig. (31) ) is a natural product found in grapes, which is present at concentrations up to 100 μM in red wines and to a much lesser extent in white wines. It has anti-inflammatory, cardiovascular protective, and cancer chemopreventive properties and was shown to target COX-1 and COX-2 isoenzymes.
It decreases COX-2 transcription and activity in human mammary epithelial cells and colon cancer cells [217, 218] . Resveratrol behaves as a non competitive inhibitor of the COX activity, suggesting that its binding site is different from AA binding site (and so different from most NSAIDs). It discriminates between COX-1 and COX-2 isoforms, being a potent inhibitor of both (COX and POX) catalytic activities of COX-1 (COX-1 IC 50 = 15 μM, COX-2 IC 50 > 200 μM by peroxidase inhibition method) [144] , and just a weak inhibitor of peroxidase activity of COX-2. It is rapidly oxidized by peroxidase activity of both COX-1 and COX-2, but in the presence of peroxides there is more COX-1 inactivation than COX-2, probably because of a different aminoacidic composition on the peroxidase domain between the two isoforms: on COX-1 active site the prevalence of oxidizable His residues could be responsible of its inactivation [139, 216] .
The m-hydroquinone moiety (3,5-di-OH group) of resveratrol is required for mechanism-based inactivation of COX-1, a finding that was confirmed by studies with resorcinol (m-hydroquinone), which identifies it as the minimal structure for COX-1 inactivation (Fig. (32) ).
The m-hydroquinone is unique because oxidation of one hydroxy group results in a semiquinone radical that can not be stabilized through the ring structure to the remaining hydroxy group, as is the case for o-and p-hydroquinones. Second, any of the three hydroxy groups on resveratrol can be oxidized by both COX-1 and COX-2; however, the outcome of these events differs with both the position of the hydroxy group and by enzyme isoform. With COX-2, all of the hydroxy groups on resveratrol can serve as reducing cosubstrates. However, with COX-1, oxidation of the mhydroquinone moiety leads to inactivation, whereas oxidation of the phenol moiety leads to reducing co-substrate activity. Therefore, with respect to COX-1, resveratrol contains moieties that make it both a mechanism-based inactivator and a reducing co-substrate, namely a m-hydroquinone and a phenol moiety on opposite rings.
Resveratrol and four of its methoxy analogs (56-59, Fig.  (31) ) were used to delineate structure-activity relationships; among methoxy-resveratrol analogues the m-hydroquinone moiety was essential for irreversible inactivation of COX-1 peroxidase and cyclooxygenase activities, while the phenol moiety acts as reducing co-substrate for COX-1 and it is not responsible of COX-1 inactivation. Oxidation of one hydroxyl group results in a semiquinone radical intermediate that can not be stabilized through the aromatic ring, thus, it could generate a protein radical inactive enzyme, like occurs in the well known self-inactivation of the COX-enzyme [220, 147] .
There has been little focus on the development of selective inhibitors or inactivators, because these compounds require a peroxide substrate to exert their effects: for this reason they lose potency in vivo because of naturally occurring reducing co-substrates that could act as antagonist of the inactivation mechanism [221] .
For this reducing properties, resveratrol has also an inhibitory effect on cytochrome P-450, anti-oxidant and antiproliferative actions [222] .
1,2-Dihydronaphtalenes and 1H-indenes (Fig. (33) ) could be considered more rigid congeners of resveratrol.
In this set only (poly)methoxylated molecules exhibited selective and potent COX-1 inhibition. In general, the inhibitory potency toward COX-1 is affected by the number of methoxy-groups as shown for both 1,2-dihydronaphthalene (60-62) and 1H-indene set (63) (64) (65) . Thus, compound 1,2-dihydro-7-methoxy-3-(2,3,4-trimetho-xyphenyl)naphthalene (62) exhibits a 25-fold higher inhibitory potency than 1,2-dihydro-7-methoxy-3-(3,4-dimethoxy-phenyl)naphthalene (Fig. (33) ).
Other Compounds (A) Curcumin Derivatives
Curcumin (Fig. (34) ), an active component of turmeric, possesses anti-inflammatory and anticancer activities [223] . Curcumin COX inhibitory activity, measured by EIA in isolated oCOX-1 and hCOX-2 isoforms, is significantly higher towards COX-1 than COX-2 (COX-1 IC 50 = 50 μM, COX-2 IC 50 >100 μM). Nurfina et al. [224] postulated that, besides olefinic double bonds, a 4-hydroxy group on the phenyl ring of curcuminoids is essential for an anti-inflammatory effect. In addition, position 3 of the aromatic ring plays an important role for the pharmacological profile, since bigger 3-alkyl groups in that position (like tert-butyl) lead to inactive molecules, whereas lower alkyl and especially 3,5-dialkylsubstituents show high oedema inhibiting activity.
A set of differently substituted curcumin analogues [225] shows a several-fold higher inhibitory activity than curcumin itself not depending on the substituent of the molecule. In particular 66, bearing a methylsulfonyl group that can be found in some COX-2 selective inhibitors, exhibits a good affinity towards COX-1 (COX-1 IC 50 = 2.68 μM, COX-2 IC 50 > 100 μM).
The bis-trimethoxyphenyl derivative (67) as well as bismethyl ester (68) exhibit very pronounced and selective COX-1 inhibition (IC 50 = 0.06 and 0.05 μM), whereas other not showed molecules had just poor affinity and selectivity towards this isoenzyme. Hence, the introduction of lipophylic and polar substituents on the phenyl ring, such as SO 2 CH 3 (66), -OCH 3 (67) and -COOCH 3 (68) , improves COX-1 selectivity of the compounds. These data were confirmed by docking experiments that revealed good van der Waals interactions and hydrogen bonding towards COX-1 isoenzyme.
(B) Sulindac Derivatives
As other NSAIDs, sulindac sulfide (Fig. (35) ) exerts its anti-inflammatory, analgesic, and anti-pyretic activities by inhibition of COX enzymes [169, 226] . It belongs to tightbinding inhibitors class, with a kinetic of inhibition consisting in a rapid reversible interaction inhibitor-enzyme followed by a slow transition to a much more tightly bound complex [164, 227] .
It has been demonstrated that the 2'-methyl group of the indene ring is an important determinant of the tight-binding of sulindac sulfide on the COX active site [228, 229] Fig. (34) . Curcumin derivatives.
the time-dependent inhibition of COX enzymes and transforms sulindac into a weaker competitive inhibitor.
Besides, the importance of the double bond geometry of the benzylidene in COX inhibition was investigated [230] . Thus, both the isomers of 2'-des-methyl sulindac sulfide were prepared and their kinetics of inhibition on COX-1 and COX-2 determined.
(E)-and (Z)-2'-des-methyl sulindac sulfides (Fig. (35) ) were evaluated as inhibitors of murine COX-2 and ovine COX-1, in different assays performed both with a saturating concentration of AA substrate (50 M) , and with reduced substrate concentrations (5 M) near the K m of COX-1 and COX-2 for arachidonate.
The data revealed that, differently from sulindac sulphide, that inhibits both COX enzymes potently, both (Z)-and (E)-2'-des-methyl sulindac sulfide exhibit COX-1/COX-2 activity significantly affected by the different substrate concentrations.
With a saturating concentration of AA substrate (50 M), (E)-2'-des-methyl sulindac sulfide exhibits no timedependent inhibition of COX-1 or COX-2, while (Z)-isomer is a very weak COX-1 and COX-2 inhibitor. These data suggest that the 2'-methyl group on the indene nucleus is one of the major determinants of time-dependent inhibition of both COX-1 and COX-2, and that the binding of the (Z)-isomer is readily reversible and consistent with competitive inhibition. With reduced substrate concentrations (5 M) near the K m of COX-1 and COX-2 for arachidonate, (E)-2'-desmethyl sulindac sulfide showed weak inhibition of COX-1 (IC 50 1.8 M) , and no inhibition of COX-2 at the concentrations tested (4 μM final concentration), while (Z)-2'-desmethyl isomer strongly inhibited both COX-1 and COX-2 under these conditions (IC 50 = 0.147 μM and 0.375 μM, respectively), demonstrating that whereas the 2'-methyl group is a critical determinant of time-dependent inhibition of COX enzymes by both (E)-and (Z)-isomers, it is less important for competitive inhibition. The geometry of the benzylidene double bond seems important for competitive inhibition as isomerisation from (Z) to (E) significantly reduces the potency against COX-1 and nearly abolishes inhibition of COX-2. It seems likely that (Z)-2'-des-methyl sulindac sulfide is oriented similarly to sulindac sulfide in the COX active site, while the E-isomer of 2'-des-methyl sulindac sulfide, selective COX-1 inhibitor, should bind in a completely different orientation in the COX active site because the different orientation of the thiomethoxyphenyl group. This compound, belonging to the arylacetic acid class, acts as a selective COX-1 inhibitor and demonstrates that selective COX-1 inhibition probably derives from a new binding mode to a COX enzyme as regards unselective classical NSAIDs.
CONCLUSIONS AND PERSPECTIVES
COX-1 isoenzyme has been receiving increasing attention in the last decade as a pharmacotherapeutic target, as it is involved in a variety of pathologies that comprise many health problems.
Through a better knowledge of COX-1 cells and tissues distribution, it has been possibile to gain a deeper under- standing of its role in pain, inflammatory syndromes in general and specifically neuro-inflammation, atherosclerosis, endothelial disfunction, pre-term labor, some type of cancers and gastrointestinal toxicity. Therefore, the development of selective COX-1 inhibitors might be highly relevant for several diseases.
With the discovery that at least two isoforms exist, it was initially clear that COX-2 was the target of inhibitors acting as analgesic, antipyretic and anti-inflammatory drugs, whereas COX-1 inhibition was responsible of gastrointestinal damage. The pharmaceutical industries made enormous investments to rapidly identify and develop selective COX-2 inhibitors to relief pain in the inflammation lacking GI effects.
Later investigations proven that neither COX-1 nor COX-2 inhibition alone is the cause of macroscopically detectable GI injury, but it is due to the contemporaneous inhibition of both isoenzymes.
Some efforts have been directed towards the development of selective COX-1 inhibitors (Fig. (2) ), but only mofezolac is clinically used as an analgesic drug just in Japan. Unfortunately, FR122047 and SC-560 abundantly used in many in vitro and in vivo studies, as potential drug candidates, failed into animal or clinical trials due to their poor pharmacodinamic properties or negative pharmacokinetic profile.
Such selective inhibitors were uncovered almost as a minor achievement during detailed structure-activity relationships investigation aimed to develop very selective COX-2 inhibitors endowed with anti-inflammatory and analgesic activity to be used in the osteoarthritis and rheumatoid arthritis treatment.
Some key structural elements can be recognized in these compounds to attempt a correlation between their structure, inhibitory potency and selectivity, even if general rules can not be stated yet.
In the case of FR122047 and mofezolac, they have in common a five member heteroaromatic central ring (thiazole in FR122047 and isoxazole in mofezolac) to which two 4-methoxyphenyls are linked at two adjacent atoms. Generally, the presence of a methylsulfonyl or sulfamoyl group shifts the selectivity towards COX-2. If electronic effects are important, methylsulfonyl and sulfamoyl groups are EWG, whereas 4-methoxy group is an EDG.
P6
and mofezolac have an isoxazole as the five member heteroaromatic core ring. As mentioned-above, mofezolac has two 4-methoxyphenyls linked to isoxazole C3 and C4. P6 brings at C3 the 5-chlorofuranyl, less hindered and capable of H-bonding by its oxygen atom, and at C4 a phenyl instead of 4-methoxyphenyl in which a hydrogen replaces the 4-methoxy group.
P9 and P10, analogues of P6, bring two phenyls at C3 and C4, respectively, and are still preferential COX-1 inhibitors. The introduction of a sulfamoyl group in para position of the phenyl at isoxazole C4 (valdecoxib) reverses the selectivity in favour of COX-2.
Then, it seems that two aromatic rings linked at adjacent atoms of a five member heteroaromatic ring is a determinant.
Thus, a number of arylsulfanilides in which the two aryls are in Z-like configuration were prepared and some were found selective COX-1 inhibitors.
On the contrary, some arylbenzanilides in which the two aryls are in E-like configuration are still preferential or selective COX-1 inhibitors. This agrees with COX-1 selectivity of indomethacin that interacts with COX-1 in s-transconfiguration.
It appears clear that more structure-activity studies are necessary to find out the structural requirements to project compounds that show selective COX-1 inhibition. Besides, more efforts are still required to better characterize, from a pharmacological point of view, the known very selective COX-1 inhibitors towards the development of drugs for the treatment or prevention of many diseases in which the COX-1 inhibition is required.
